Stevanato Group

Stevanato Group operates globally as a leading provider of integrated drug containment, drug delivery, diagnostic solutions, and related engineering services. The company does not conduct clinical trials or have its own therapeutic pipeline but enables pharmaceutical development from early-stage to commercial launch through its products and services. It has demonstrated strong growth in revenue (€1.104 billion in FY2024) and continues to expand manufacturing capacity worldwide. Recent innovations include advanced primary packaging for biologics/mRNA therapies, sustainable on-body injectors, high-resistance vials (Nexa®), pre-fillable syringes/cartridges (EZ-Fill®), custom IVD devices, vision inspection equipment, assembly automation lines, analytical testing labs in the US/EU/Japan. The group invests heavily in R&D (~4% of turnover) to support technical innovation. No clinical results or programs as it does not develop drugs directly. Market leader status in RTU/bulk cartridges for pen injectors/pre-fillable syringes/presterilized vials. Listed on NYSE since July 2021 under symbol STVN. Over 4,300 employees across more than nine countries with major sites in Italy HQ/Piombino Dese; Fishers IN USA; Slovakia; Brazil; Japan office; Boston MA Tech Center. Revenue FY2024 €1.104 billion ($1.2B). Founded in Italy in 1949.